Conformis, Inc.

NasdaqCM:CFMS Stock Report

Market Cap: US$17.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Conformis Management

Management criteria checks 3/4

Conformis' CEO is Mark Augusti, appointed in Nov 2016, has a tenure of 6.83 years. total yearly compensation is $1.67M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 2.19% of the company’s shares, worth $389.85K. The average tenure of the management team and the board of directors is 3.2 years and 14.6 years respectively.

Key information

Mark Augusti

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage34.72%
CEO tenure6.8yrs
CEO ownership2.2%
Management average tenure3.2yrs
Board average tenure14.6yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 13

Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip system

Conformis (NASDAQ:CFMS) stock jumped ~17% after hours on Tuesday after the firm received 510(k) clearance from the U.S. Food and Drug Administration for its Actera hip system. Actera uses an advanced tri-taper femur stem design to facilitate a minimally invasive approach similar to direct anterior approach. CFMS will introduce Actera under a limited market release in select U.S. markets, expected to start in the coming months.
Seeking Alpha • Aug 01

Conformis signs agreement with Vizient for personalized orthopedic implants

Medical device firm Conformis (NASDAQ:CFMS) said it had entered into a multi-year agreement with Vizient to offer its personalized orthopedic implants. (CFMS) is trading 5.9% higher after the bell. The agreement gives access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers.
Analysis Article • Jan 11

Investors Will Want Conformis' (NASDAQ:CFMS) Growth In ROCE To Persist

If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
Analysis Article • Dec 21

We Think Conformis (NASDAQ:CFMS) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Nov 11

What Does Conformis, Inc.'s (NASDAQ:CFMS) Share Price Indicate?

Conformis, Inc. ( NASDAQ:CFMS ), is not the largest company out there, but it received a lot of attention from a...
Analysis Article • Sep 16

Is Conformis (NASDAQ:CFMS) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Sep 04

Conformis: Emerging Surgical Implant Developer

Conformis is a small company developing knee and hip replacement implants. They have recent collaboration deals with major players. The company has a decent cash balance, but revenue growth is impacted by the pandemic.
Analysis Article • Aug 11

Shareholders Shouldn’t Be Too Comfortable With Conformis' (NASDAQ:CFMS) Strong Earnings

Strong earnings weren't enough to please Conformis, Inc.'s ( NASDAQ:CFMS ) shareholders over the last week. Our...
Analysis Article • Aug 10

Party Time: Brokers Just Made Major Increases To Their Conformis, Inc. (NASDAQ:CFMS) Earnings Forecasts

Celebrations may be in order for Conformis, Inc. ( NASDAQ:CFMS ) shareholders, with the analysts delivering a...
Analysis Article • May 18

Increases to Conformis, Inc.'s (NASDAQ:CFMS) CEO Compensation Might Cool off for now

In the past three years, the share price of Conformis, Inc. ( NASDAQ:CFMS ) has struggled to grow and now shareholders...
Analysis Article • May 11

Analysts Just Shipped An Incredible Upgrade To Their Conformis, Inc. (NASDAQ:CFMS) Estimates

Conformis, Inc. ( NASDAQ:CFMS ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • May 08

Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jan 16

Is Conformis (NASDAQ:CFMS) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

CEO Compensation Analysis

How has Mark Augusti's remuneration changed compared to Conformis's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$44m

Dec 31 2022US$2mUS$579k

-US$50m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$2mUS$552k

-US$2m

Sep 30 2021n/an/a

US$7m

Jun 30 2021n/an/a

US$14m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$552k

-US$24m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$3mUS$536k

-US$28m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$1mUS$536k

-US$43m

Sep 30 2018n/an/a

-US$45m

Jun 30 2018n/an/a

-US$50m

Mar 31 2018n/an/a

-US$48m

Dec 31 2017US$2mUS$520k

-US$54m

Sep 30 2017n/an/a

-US$57m

Jun 30 2017n/an/a

-US$58m

Mar 31 2017n/an/a

-US$60m

Dec 31 2016US$1mUS$69k

-US$58m

Compensation vs Market: Mark's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD756.14K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Augusti (57 yo)

6.8yrs
Tenure
US$1,666,832
Compensation

Mr. Mark A. Augusti has been Chief Executive Officer and President at ConforMIS, Inc. since November 14, 2016. Mr. Augusti's 27-year business career has been marked with executive management responsibility...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Augusti
CEO, President & Director6.8yrsUS$1.67m2.19%
$ 389.8k
Denise Pedulla
Chief Legal Officer & Corporate Secretary1.5yrsUS$991.22k0.018%
$ 3.3k
Christine Desrochers
Interim CFO & Corporate Controller3.2yrsno data1.03%
$ 184.1k
Michael Fillion
Chief Operating Officer1.4yrsno datano data
Eric Rickenbach
Senior Vice President of US Salesno datano datano data
Terrance Wong
Senior Vice President of Engineering & Regulatory2.5yrsno datano data
Erin Henry
Corporate Controller5.8yrsno datano data
Daniel Steines
Consultant4.9yrsUS$888.98kno data
3.2yrs
Average Tenure
55.5yo
Average Age

Experienced Management: CFMS's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Augusti
CEO, President & Director6.8yrsUS$1.67m2.19%
$ 389.8k
Kenneth Fallon
Independent Chairman of the Board18.7yrsUS$176.17k0.26%
$ 45.9k
Bradley Langdale
Independent Director15.3yrsUS$139.67k0.23%
$ 41.5k
Klaus Radermacher
Member of Scientific Advisory Board12.4yrsno datano data
Brian McKeon
Member of the Scientific Advisory Board14.6yrsno datano data
Thomas Thornhill
Member of Scientific Advisory Boardno datano datano data
Thomas Minas
Member of Scientific Advisory Boardno datano datano data
Wolfgang Fitz
Member of Scientific Advisory Boardno datano datano data
Richard Scott
Member of Scientific Advisory Board14.8yrsno datano data
Amar Ranawat
Member of the Scientific Advisory Board14.6yrsno datano data
Anil Ranawat
Member of the Scientific Advisory Board14.6yrsno datano data
Mahmoud Hafez
Member of Scientific Advisory Board12yrsno datano data
14.6yrs
Average Tenure
59yo
Average Age

Experienced Board: CFMS's board of directors are seasoned and experienced ( 14.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/06 23:49
End of Day Share Price 2023/09/01 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Conformis, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory ChodaczekB. Riley Securities, Inc.
Michael GormanBTIG
Kyle RoseCanaccord Genuity